AQR Arbitrage’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-6,953,621
Closed -$35.7M 584
2019
Q4
$35.7M Buy
6,953,621
+85,650
+1% +$435K 0.6% 40
2019
Q3
$35.4M Sell
6,867,971
-47,240
-0.7% -$264K 0.52% 39
2019
Q2
$41.8M Buy
6,915,211
+164,084
+2% +$1.15M 0.48% 53
2019
Q1
$48.8M Buy
6,751,127
+166,229
+3% +$1.2M 0.61% 40
2018
Q4
$48.7M Buy
+6,584,898
New +$41.7M 0.67% 40

Other funds holding PACB

AQR Arbitrage's PACB Position: Q1 2020 in Review

AQR Arbitrage sold out of Pacific Biosciences (PACB) in Q1 2020, closing a stake of 6,953,621 shares — an estimated $35.7M sold.

AQR Arbitrage first reported a position in PACB in Q4 2018 and held it in 5 quarters. The position peaked at $48.8M in Q1 2019. 132 funds tracked by Wall St. Rank hold PACB as of Q1 2020.

  • AQR Arbitrage reported no remaining Pacific Biosciences position as of Q1 2020 after selling out during the quarter.
  • AQR Arbitrage sold 6,953,621 Pacific Biosciences shares in Q1 2020, an estimated $35.7M.
  • AQR Arbitrage first reported a position in Pacific Biosciences in Q4 2018 and held it in 5 quarters.
  • AQR Arbitrage's Pacific Biosciences position peaked at $48.8M in Q1 2019.
  • 132 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2020.

Based on AQR Arbitrage's 13F filing for Q1 2020, filed 15 May 2020.